indazoles has been researched along with Leukemia, Lymphoblastic, Acute, T Cell in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aster, JC; Craig, JW; Dail, M; Downing, JR; Hasserjian, RP; Hayes, K; Huang, BJ; Jonsson, P; Kogan, SC; Li, Q; Meyer, LK; Monsalve, G; Nakitandwe, J; Sampath, D; Scacchetti, A; Shannon, K; Taylor, BS; Wandler, AM; Weinberg, O; Wong, JC; Yamamoto, K; Yan, H; Zhang, J | 1 |
| Donker, L; Ducker, GS; Jun, J; Ksionda, O; Matlawska-Wasowska, K; Mues, M; Roose, JP; Shannon, K; Shokat, KM; Tenhagen, M; Wandler, AM | 1 |
| Akagi, K; Aster, JC; Chen, SC; Dail, M; Downing, JR; Lawrence, J; Lee, LB; Li, Q; Nakitandwe, J; O'Connor, D; Pear, WS; Sampath, D; Shannon, K; Wong, J; Xu, J | 1 |
| Bressanin, D; Buontempo, F; Chiarini, F; Evangelisti, C; Martelli, AM; McCubrey, JA; Melchionda, F; Pagliaro, P; Pession, A; Ricci, F; Tabellini, G; Tazzari, PL | 1 |
5 other study(ies) available for indazoles and Leukemia, Lymphoblastic, Acute, T Cell
| Article | Year |
|---|---|
Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia.
Topics: Animals; Dexamethasone; Drug Resistance, Neoplasm; Humans; Indazoles; Male; Mice; Mice, Inbred C57BL; Mutation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Glucocorticoid; Recurrence; Sulfonamides | 2020 |
Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Topics: Animals; Apoptosis; Cell Proliferation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Mice, Inbred C57BL; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.
Topics: Animals; Benzamides; Clone Cells; Diphenylamine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Genes, ras; Indazoles; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase Kinases; Phosphoinositide-3 Kinase Inhibitors; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Receptor, Notch1; Signal Transduction; Sulfonamides | 2014 |
NOTCH1 downregulation contributes to PI3K inhibitor resistance in T-ALL.
Topics: Animals; Drug Resistance, Neoplasm; Indazoles; Male; Phosphoinositide-3 Kinase Inhibitors; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Receptor, Notch1; Sulfonamides | 2014 |
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
Topics: Adult; Caspase 3; Cell Line, Tumor; Child; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; Signal Transduction; Sulfonamides; T-Lymphocytes; TOR Serine-Threonine Kinases | 2012 |